Spotlight on MRA’s Ninth Annual Scientific Retreat
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 28 February 2017 In Allies & Partnerships, Events, Science
In mid-February, MRA held its premiere research event — the 9th Annual Scientific Retreat, in Washington, DC. A total of 297 individuals registered for the meeting representing a spectrum of key stakeholders in melanoma including academic investigators, pharmaceutical and biotech company representatives, melanoma advocates from various different non-profit organizations, donors and government officials.
Melanoma Prevention: The Latest Advances & Future Directions
During my interview with Susan Swetter, MD, Professor of Dermatology,
Stanford University and VA Palo Alto, at the Melanoma Research Alliance Ninth Annual Scientific Retreat in Washington, DC, I inquired about the Panel Discussion she was part of titled: News from the field: What’s going well and what remains to be done?
MRA’s Young Investigator Program: Bringing New Talent & Novel Ideas for Research Forward
In February, at the Ninth Annual MRA Scientific Retreat, a Young Investigator Breakfast brought together scores of past and current MRA Young Investigators where I connected with one of MRA’s first young investigators, Dr. Timothy Bullock.
The Power of Combination Therapies: One Patient’s Road to Remission
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 28 February 2017 In Science, Treatment
Metastatic melanoma can be a devastating diagnosis to receive. Just hearing the word cancer for most is terrifying. While the fear is understandable, today new targeted therapies and immunotherapies are delivering new hope for many.
Melanoma 2016 — the Year in Review
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 20 January 2017 In News
In the nearly 10 years since MRA’s founding in 2007, there has been extraordinary progress for melanoma. With 11 new treatments approved since 2011, it began to feel like frequent new drug approvals was the current norm.
Understanding Neoantigens: A Critical Target for Improving Immunotherapy
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 20 January 2017
The approval of eleven new therapies for melanoma since 2011 has led to dramatic changes in how doctors treat melanoma and even more importantly, has led to better outcomes for many patients. Chief among the new therapies are those that target the immune system.
Melanoma Immunotherapy and Precision Medicine — a Medical Student’s Perspective
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 20 January 2017 In Science
Malignant melanoma research has provided the perfect opportunity to explore the intersection of immunotherapy and precision medicine, which has greatly transformed melanoma therapeutics in the last decade.
To say that Tara Miller inspired mixed emotions is to begin to understand her life. The strong-willed survivor, who lost her battle to melanoma in 2014, reflected the contradictions that define an indomitable will to live.
Parallels between Disease States
Six months ago I was offered the opportunity to serve as President & CEO of MRA and in July, I officially began. For the past 24 years, I’ve worked in the HIV field and am struck by the many parallels that exist between my past work and melanoma.
Uncommon Immunotherapy Side Effects
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 November 2016
A recent report in the prestigious New England Journal of Medicine (NEJM), has spawned reports like this one, regarding the risk of death in patients treated with combination checkpoint treatments. The first author of the NEJM story is MRA-funded investigator, Doug Johnson at Vanderbilt.
Accelerated Approval Advocacy Allies Anti-PD-1 ASCO Awareness Biopharma biopsy Board Members BRAF Cancer Capitol Hill Clinical Trials Collaborations Combination Therapies Combination Therapy Congress Corporate Partners Detection Diagnostics Drug Development Events Expanded Access Program FDA Francis Collins Funding Fundraising Genetics Health HHS immune checkpoint inhibitors Immunotherapies Immunotherapy Indoor Tanning ipilimumab Kids Legislation Leveraged Finance Fights Melanoma LFFM Louise Perkins May Medical Research Melanoma Melanoma Awareness Melanoma Awareness Month Melanoma Prevention Melanoma Research Melanoma Survivors MRA MRA Researchers News NIH Nonprofits Partnering Partnering For Cures Partnerships PASS Coalition Patient Advocacy Patient Story Patient-Centric Care Patients Pediatric Melanoma Policy Prevention Redheads Research research collaboration research funding research grants Researchers Science Sequestration skin biopsy Skin Cancer Skin Cancer Prevention Skin Checks Social Media Sun Safety Sunburn Sunscreen Sunscreen Innovation Act Surgeon General Surgeon General\'s Call to Action to Prevent Skin Cancer Survivor Story Tanning Tanning Bans Tanning Bed Tanning Bed Ban Tanning Beds targeted therapy Teens Treatment Treatments UPF Clothing Wendy Selig young investigator awards Young People